Real-world patient outcomes with Blinatumomab and Inotuzumab in adult relapsed/refractory B-cell acute lymphoblastic leukemia: a retrospective analysis from two Romanian oncology centers.

ABSTRACT:

Introduction

The management of adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a significant challenge, with patients presenting particularly poor historical outcomes. Novel immunotherapies, such as Blinatumomab and Inotuzumab, have revived the therapeutic landscape of R/R B-ALL, but their optimal sequencing, toxicity management, and post-transplant integration remain unclear, particularly in real-world, resource-limited settings.

Methods

We conducted a retrospective analysis of 33 adult patients with R/R B-ALL treated between 2019 and 2023 at two major oncology centers in Romania.

Results

Blinatumomab and Inotuzumab achieved complete remission rates of 47.6% and 90%, respectively, with measurable residual disease negativity in over 6

SUBMITTER: Antohe I 

PROVIDER: S-EPMC12728000 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature